1Peters RJ,Mehta SR,Fox KAA,et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes:Observations from the clopidogrel in unstable angina to prevent recurrent events(CURE)study[J].Circulation,2003,108(14):1 682.
2Tendera M,Wojakowski W.Role of antiplatelet drugs in the prevention of cardiovascular events[J].Thromb Res,2003,110 (5～ 6):355.
3Mckee SA,Sane DC,Deliargyris EN.Aspirin resistance in cardiovascular disease:A review of prevalence,mechanisms,and clinical significance[J].Thromb Haemost,2002,88(5):711.
6Gum PA,Kottke-Marchant K,Poggio ED,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88(3):230.
7Catella-Lawson F,Reilly MP,Kapoor SC,et al.Cyclooxygenase inhibitors and the antiplatelet effects of aspirin[J].N Engl J Med,2001,345(25):1 809.
8Hankey GJ,Eikelboom JW.Aspirin resistance:May be a cause of recurrent ischaemic vascular events in patients taking aspirin[J].BMJ,2004,328(7 438):477.
9Kurth T,Glynn RJ,Walker AM,et al.Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal nti-inflammatory drugs[J].Circulation,2003,108(10):1 191.
10Cerletti C,Dell' Elba G,Manarini S,et al.Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes[J].Clin Pharmacokinet,2003,42(12):1 059.
2Caplain H, Donat F, Gaud C, et al. Pharmacokinetics of clopidogrel[J] . Seminars in Thrombosis and Hemostasis, 1999,25(2) :25.
3Pascal M, Herbert JM, Maffrand JP, et al. Structure and stereochemistry of the active metabolite of clopidogrel[J ] . Drug Metabolism and Disposition , 2002, 30:1 288.
4Ramakrishna VSN, Vishwottam NK, Manoj S, et al .Quantification of clopidogrel in human plasma by sensitive liquid chromatography/ tandem mass spectrometry[J ] . Rapid Communications in Mass Spectrometry, 2006,20(20) : 1 695.
5Robinson A, Hillis J ,Neal C, et al .The validation of a bioanalytical method for the determination of clopidogrel in human plasma[J] . Journal of Chromatography B, 2007,848(4) : 344.
6SOLYMOSS B C,BOURASSA M G,CAMPEAU L A,et al.Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity[J].Am J Cardiol,2004,93(2):159.
7Ridker P M.High-sensitivity C-reactive protein:potenfial adjunct for global risk assessment in the ptimmy prevention of cardiovascular disease[J].Circulation,2001,103(13):1813.
8Koenig W,Lowd lq,Baumert J,et al.C-reactive protein modulates risk prediction based on the Framinghm score:implications for future risk assessment:results from a Iarge cohort study in southern Germany[J].Circuhfion,2004,109(10):1349.
9Barath P,Fishbein CM,Cao J,eI a1.Detection and localization 0f TNF in human atheroma[J].Am J Cardiol,1990,65(4):297.
10Mallat Z,Corbaz A,Seoazee A,et al.Interleukin-18 /Interleukin-18 binding protein signaling modulates atheroselerotic lesion development and stability[J].Circ Res,2001,89:41.
